Welcome to the BASIL-2 Trial Webpage

Recent publication by Kevin Barraclough and Professor Andrew Bradbury (BASIL-2 CI) on "Chronic limb threatening ischaemia"; Read the article here.

The 'BASIL Trials Investigator Meeting' at the VSGBI Annual Scientific Meeting (23rd November 2017); View the presentation here.

Recently published subgroup analysis by Popplewell et al. of patients randomised into the original BASIL trial with infrapopliteal disease reafirming the need for RCTs such as BASIL-2 and BEST-CLI; Read the article here.

Retrospective analysis by Darling et al. demonstrating "improved 6-month wound
healing, higher freedom from restenosis, improved patency rates, significantly fewer reinterventions, and higher survival [within 3 years]" for primary bypass over primary angioplasty /stent; Read the article here

Article by Barry Katzen on "Endovascular therapy for critical limb ischaemia: When is enough, enough?"; Read the article here.  


Basil 2 is a multi-centre randomised controlled trial to find out if a ‘vein bypass first’ or a ‘best endovascular first’ revascularisation strategy is best, in terms of either clinical or cost-effectiveness, for severe limb ischaemia due to infra-popliteal disease.

Severe limb ischemia is the most severe form of lower limb peripheral artery disease and is a seriously disabling, life and limb threatening, condition. The aim of BASIL-2 is to evaluate the effectiveness and cost-effectiveness of these interventions  for people with severe limb ischaemia.


The BASIL-2 Trial is funded by a NIHR Health Technology Assessment grant (project number 12/35/45)

Trial Progress

Basil-2 officialy began its recruitment phase in July 2014 with its first randomisation from the lead centre (Heart of England NHS Foundation Trust).

As of 24 Jan 2018, a total of 40 clinical centres are open to recruit to the Basil-2 trial; 29 in England, 5 in Scotland, 2 in Wales, 3 in Denmark, and 1 in Sweden.  Thirty-nine of the 40 clinical centres have cumulatively recruited 256 participants. 

BASIL-2 Trial Centres

BASIL-2 Trial Centres
Trial Centre Date Green Light Issued
 Heartlands 11/06/2014 
 Newcastle General 11/07/2014 
 Southampton 02/09/2014 
 Russell's Hall 29/09/2014 
 Hull & York Hospitals 30/09/2014 
 North Durham 17/10/2014 
 Sheffield 17/10/2014 
 South Manchester 21/10/2014 
 Aberdeen 07/11/2014 
 Leeds Teaching Hospital 10/11/2014 
 Worcester 02/12/2014 
 Imperial 10/12/2014 
 Royal Free, London 12/12/2014 
 Guy's and St. Thomas' 13/01/2015 
 Royal Cornwall 03/02/2015 
 UHB 06/02/2015 
 Sandwell & West Birmingham Hospital 09/02/2015 
 St George's 16/02/2015 
 North Cumbria 16/02/2015 
 Leicester 04/03/2015 
 Western Infirmary, Glasgow 04/03/2015 
 Frimley Park 09/03/2015 
 Royal Infirmary, Edinburgh 20/03/2015 
 UHCW 27/03/2015 
 Oxford 24/04/2015 
 Northwest London (Northwick Park) 28/05/2015 
 Manchester Royal 28/05/2015 
 Ninewells, Dundee (NHS Tayside) 17/06/2015 
 Addenbrookes 23/06/2015 
 Royal Bournemouth 24/07/2015 
 James Cook 27/07/2015
 Kent & Canterbury 27/07/2015 
 Norfolk & Norwich 10/08/2015 
 Cardiff (UHW) 13/08/2015 
 Royal Sussex 19/08/2015 
 Royal Oldham 14/09/2015 
 Colchester General 22/09/2015 
 Doncaster Royal Infirmary 28/09/2015 
 Barts and the London 02/10/2015
 York 14/10/2015
 Torbay 25/11/2015
 Royal Blackburn 03/12/2015 
 United Lincolnshire Hospitals 06/01/2016 
 Gloucester Hospitals 29/01/2016 
 Portsmouth (Queen Alexandra) 01/03/2016 
 Taunton 16/03/2016
 Kolding (Denmark) 18/04/2016 
 Royal Preston 11/05/2016 
 Southmead (Bristol) 16/05/2016
Bradford Royal Infirmary 14/09/2016
Sodersjukhuset (sweden) 01/12/2016
Aarlborg (Denmark) 03/04/2017
Stirling (NHS Forth Valley) 04/04/2017
Odense (Denmark) 12/06/2017

You can also see our clinical centres on the map.

Current BASIL-2 Recruitment (Updated 23 Feb 2018)

B2 Recruitment Target 23022018

For a more in depth overview of recruitment to BASIL-2, visit our recruitment page.